Desperate Patients Want a New ALS Drug. The FDA Is Not Sure It Works

Jinsy Andrews, director of neuromuscular clinical trials at Columbia University and an investigator in the 600-patient Amylyx study, said there is plenty of evidence enabling the FDA to approve AMX0035 now. And she argues there are big differences between Aduhelm and AMX0035. [read more] 
Note: Accessing this article requires The Washington Post subscription.

Source: The Wall Street Journal